ZymoGenetics Inc. announced unaudited earnings results for the third quarter and nine months ended September 30, 2009. For the quarter, the company's net loss declined substantially to $11.4 million, or $0.17 per basic and diluted share compared to net loss of $28.8 million, or $0.42 per basic and diluted share on the revenue of $11.9 million for the third quarter of 2008. Revenues for the third quarter of 2009 increased by 131% compared to the third quarter of 2008 as a result of increased sales of RECOTHROM(R) Thrombin, topical (Recombinant) and higher collaboration and license revenues. The company reported loss from operations of $9.3 million and net loss before income tax benefit of $11.8 million compared to loss from operations of $34.1 million and net loss before income tax benefit of $28.8 million for the same period last year. For the nine months, the company reported net loss of $56.5 million or $0.82 basic and diluted per share on the revenue of $74.9 million compared to net loss of $107.06 million or $1.56 basic and diluted per share on the revenue of $38 million for the same period last year. The company reported loss from operations of $49.8 million and net loss before income tax benefit of $56.9 million compared to loss from operations of $111.2 million and net loss before income tax benefit of $107 million for the same period last year.

ZymoGenetics Inc. reported revenue results for the third quarter of 2009. For the quarter, the company's revenue increased 131% to $8.5 million, from the year-ago quarter, due to sales of Recothrom.

Bristol-Myers Squibb Co. and ZymoGenetics Inc. presented final results from a Phase 1b clinical trial of PEG-Interferon lambda administered with ribavirin in relapsed and treatment-naive hepatitis C virus (HCV) patients. The poster included data on 56 patients in the study. Antiviral activity was observed at all dose levels tested. The results will be presented at the American Association for the Study of the Liver Diseases annual meeting in Boston on November 3. Interim results were previously presented at the European Association for the Study of the Liver annual meeting in April 2009. The Phase 1b clinical trial was designed to evaluate the safety and antiviral activity of PEG-Interferon lambda when given as a single agent or in combination with ribavirin in genotype 1 HCV patients with relapsed disease and in treatment-naive patients. In the single agent arm of the study with treatment-relapsed patients (n=24), PEG-Interferon lambda was administered subcutaneously at 1.5 mcg/kg and 3.00mcg/kg weekly for four weeks, and 1.5 mcg/kg and 3.00 mcg/kg every two weeks. In the combination arm of the study with treatment-relapsed patients (n=24), PEG-Interferon lambda was administered subcutaneously weekly at 0.5 mcg/kg, 0.75 mcg/kg, 1.5 mcg/kg and 2.25 mcg/kg for four weeks, with daily oral ribavirin administered consistent with the package insert. Patients in the cohort of treatment-naive patients (n=7) were given 1.5 mcg/kg of PEG-Interferon lambda and ribavirin.